## Long COVID Evidence Update

Table of Contents

[Long COVID Evidence Update 1](#_Toc120870009)

[Document Summary 2](#_Toc120870010)

[Introduction 4](#_Toc120870011)

[Limitations 4](#_Toc120870012)

[Long COVID terminology and definitions 5](#_Toc120870013)

[Symptoms and Signs 6](#_Toc120870014)

[Omicron 8](#_Toc120870015)

[Epidemiology 9](#_Toc120870016)

[Prevalence 9](#_Toc120870017)

[Prevalence of long COVID in Aotearoa New Zealand 10](#_Toc120870018)

[Aetiology 11](#_Toc120870019)

[Similarities between long COVID and ME/CSF 11](#_Toc120870020)

[Risk factors 12](#_Toc120870021)

[Risk of long COVID after reinfection 13](#_Toc120870022)

[Long COVID in children 13](#_Toc120870023)

[Prevention through vaccination 14](#_Toc120870024)

[Vaccination prior to infection 15](#_Toc120870025)

[Vaccination after infection 15](#_Toc120870026)

[Vaccine injury 17](#_Toc120870027)

[Impacts 17](#_Toc120870028)

[Psychosocial impacts 17](#_Toc120870029)

[Social and economic impacts 17](#_Toc120870030)

[Management and Support 18](#_Toc120870031)

[Diagnosis 18](#_Toc120870032)

[Treatment 19](#_Toc120870033)

[Models of care 19](#_Toc120870034)

[Models of care in Aotearoa New Zealand 20](#_Toc120870035)

[Evaluation of services 21](#_Toc120870036)

[International guidelines on rehabilitation and management 22](#_Toc120870037)

[Policy responses 23](#_Toc120870038)

[References 25](#_Toc120870039)

### Document Summary

* The New Zealand definition of long COVID was outlined in the Clinical Rehabilitation Guideline for People with long COVID in Aotearoa New Zealand on 15 September 2022. [1] Long COVID is defined as signs and symptoms consistent with COVID-19, that develop during or after an infection, continues for more than 12 weeks and are not explained by an alternative diagnosis.
* The range of symptoms experienced by individuals who develop long COVID is broad, with studies indicating that over 100 symptoms have been associated with long COVID. [2, 3]
* Various studies have reported a wide range of estimates for long COVID prevalence, ranging from single digits to at least 80%. [2, 4] In a global meta-analysis published in April 2022, hospitalised and non-hospitalised patients had estimates of 0.54 (95% CI, 0.44-0.63) and 0.34 (95% CI, 0.25-0.46) respectively, indicating that a significant proportion of patients may develop long COVID, particularly if they were hospitalised during the acute infection. [5] The prevalence of long COVID is difficult to determine for several reasons. For example, studies may use different definitions of long COVID, focus on different groups of people, assess different time periods post-infection, and use different methods to collect data.
* The prevalence of long COVID in Aotearoa New Zealand is currently unknown, however some recently funded studies will help give a better picture following the development of clinical codes for long COVID. [6]
* While data is still emerging, it is likely that Māori will be disproportionately affected by long COVID. Māori continue to experience inequities in vaccination rates and incidence of severe illness requiring hospitalisation[[1]](#footnote-2), both of which are associated with a higher likelihood of developing long COVID.
* The aetiology of long COVID is complex and there is likely to be more than one mechanism that contributes to its development. Evidence continues to emerge on the molecular contributors to long COVID, which may inform advice for management and treatment. SARS-CoV-2 is not just a virus that affects the respiratory system; it can cause widespread tissue damage and inflammation, leading to multisystem disruption, systemic inflammation, and immune dysfunction. [8, 9]
* Many healthcare professionals and researchers have compared the experience of long COVID to other post-viral conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). [10-12] Similarities include a pattern of long-term illness triggered by acute viral infection, comparable symptoms/demographics, and a poor understanding of underlying mechanisms.
* A range of factors associated with an increased risk of developing long COVID have been identified. Some of these include older age, being female, multiple early symptoms, obesity, and some pre-existing conditions such as asthma. A range of immunological factors may also play a role.
* Reinfection with SARS-CoV-2 is becoming more common due to waning of immunity and increased immune evasion from emerging new variants. The translation of COVID-19 reinfections to long COVID incidence is currently unknown and difficult to quantify, however it reflects the unique position of Aotearoa New Zealand which had a highly vaccinated population prior to community transmission of Omicron and subsequent variants. Emerging research overseas is generally showing the acute and lingering symptoms for an Omicron infection to be less severe than with earlier variants. [13]
* Vaccination remains the most accepted form of prevention from long COVID. There is a substantial amount of literature emerging that supports the hypothesis that getting vaccinated prior to infection reduces the risk of long COVID. [14-24] The exact effect of vaccination on pre-existing long COVID remains uncertain and contentious. Anecdotal reports and studies suggest a variety of experiences following COVID-19 vaccination ranging from improvement, deterioration, and no change in long COVID symptoms. [15, 17, 23, 25-27]
* There are no specific tests used by healthcare professionals to diagnose long COVID. Diagnosis is instead based on presentation of long COVID symptoms following a known or suspected SARS-CoV-2 infection. There are a wide range of symptoms that can present for long COVID, many of which are common to a multitude of other conditions, making them hard to decipher or confirm as long COVID. [28]
* Diagnostic techniques are emerging, most use immune profiling techniques and machine learning to identify biomarkers associated with inflammation. It remains clinically unproven if tests differentiate between long COVID and other similar conditions. One paper has found cortisol levels appear to be the most significant predictor of long COVID. [29]
* Multiple potential long COVID therapeutics are in development, however none so far are clinically proven. Clinical trials investigating long COVID treatments are currently limited by having small sample sizes, sub-optimal control groups and target specific symptoms. Some potential therapeutic options being explored include Paxlovid, SNG001 (by Synairgen), antihistamines and dietary supplements. [30-33]
* Globally the development and implementation of policies relating to the funding, development, and maintenance of services to treat long COVID is ongoing.

### Introduction

In the early stages of the pandemic, most attention was focused on the acute health impacts of SARS-CoV-2 infection. [34] It was initially thought that although some people have a prolonged and complicated hospital stay, most people recover from ‘mild’ infections within two weeks and from more serious disease within three weeks. [35] However, it has become clear that for some people COVID-19 can lead to persistent illness, with ongoing and often debilitating symptoms. [35-37]

This document is a summary of the current evidence known about the long-term health impacts of COVID-19, often referred to as long COVID, and the experiences of people living with long-term complications of COVID-19. It is a collation of expert opinion and the latest scientific and technical research exploring the ongoing nature or long-term presentation of signs and symptoms that appear or continue to occur after the acute phase of COVID-19, and discusses aetiology, epidemiology, issues related to the impact of vaccination and new emerging variants. Additionally, it includes developments in international guidance from peak bodies on diagnosis, management, support, and rehabilitation pathways. It reflects current knowledge at the time of writing (November 2022). New evidence in this update will be in red text. This evidence brief consolidates the information previously provided.

### Limitations

This evidence brief has some notable limitations. The document aims to give an overview of currently available evidence on various aspects of long COVID. While comprehensive, it is not a systematic review and as such some relevant material may have been inadvertently missed. Long COVID is still a relatively new condition, and many questions remain to be answered. Research is ongoing to better understand the causes, risk factors, clinical course, and possible treatments. Clinical trials investigating long COVID-19 treatments currently are limited by often having small sample sizes, sub-optimal control groups and investigate impact on specific symptoms, such as fatigue or thrombotic events.

The prevalence of long COVID is difficult to establish for many reasons. [2, 38-40] It can be difficult to reliably compare studies of different types and populations, partly because the prevalence of long COVID may vary greatly depending on the groups studied. For example, studies of patients who were hospitalised for COVID-19 tend to find significantly higher rates of long COVID than studies of patients who were not hospitalised. Other complicating factors include:

* Studies may use different definitions of long COVID, focus on different groups of people, assess different time periods post-infection, and use different sample sizes
* There is no specific test to diagnose long COVID, and people may have a wide variety of symptoms that could be related to other health problems
* Published studies may not be representative of everyone who has long COVID
* The ways in which responses are elicited can impact estimated prevalence (e.g., app users are self-selected and responsible for recording symptoms, which can result in sampling and recording biases). Surveys that investigate symptoms retrospectively may be at particular risk of recall bias
* Most long COVID studies lack control groups, making it difficult to draw a causal link between COVID-19 infection and the reported symptoms.

Long COVID in children remains not well described. There are many limitations which directly affect the strength of outcomes and comparability between studies. These limitations include a lack of a clear case definition, arbitrary follow up time points, subjective assessment, lack of control groups, small population size and low response rates. Often in studies which include young children and infants’ data is collected through questioning from parents and caregivers which can also create recall bias. [41-44]

With respect to the impact of vaccination on long COVID, the lack of randomised controlled trials and predominance of observational studies means that causality cannot be determined easily. Long COVID studies exploring the impact of vaccination have generally been small, with self-selected participants and sub-optimal control cohorts. [19] Many studies exclude hospitalised patients, and therefore conclusions may not apply to people who had severe disease. The effect of different vaccines, doses, and dosing schedules on long COVID is also difficult to disentangle. Varying levels of prior exposure and natural immunity between populations, as well as waning immunity and evolving definitions of vaccination status, are further complicating factors.

### Long COVID terminology and definitions

Ongoing symptoms are common following many viral and bacterial infections, including other coronaviruses. The term ‘long COVID’ is generally used to describe persistent or developing signs and symptoms following acute COVID-19. Symptoms may persist for weeks or months causing significant impact on affected individuals, their family and whānau.

Throughout international literature, long COVID is referred to by many names, including post-COVID-19 syndrome, long-haul COVID, post-acute COVID-19, post-acute sequelae of SARS CoV-2 infection, long-term effects of COVID, and chronic COVID.

**There is no internationally agreed definition of the long COVID condition yet.**

Aotearoa New Zealand will have a unique long COVID profile due to the early successes in transmission reduction in the pandemic. The low prevalence of COVID-19 in Aotearoa New Zealand prior to Omicron has resulted in a proportionally low incidence of long COVID prior to 2022. However, with the arrival of Omicron and its sub-lineages and Aotearoa New Zealand now having had over 1.83 million reported cases of COVID-19, an increase in long COVID cases is expected.

It has been agreed to adopt the clinical case definitions from the joint guideline used by the National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN) and the Royal College of General Practitioners (RCGP) to distinguish between acute and long COVID cases, as follows: [45]

* Acute COVID 19:
	+ Signs and symptoms for up to 4 weeks
* Ongoing symptomatic COVID-19:
	+ Signs and symptoms of COVID-19 from 4 weeks up to 12 weeks
* Post-COVID-19 syndrome:
	+ Any signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis. Presentation may include clusters of symptoms, often overlapping, which can fluctuate and change over time and can affect any system in the body
	+ Post-COVID-19 syndrome may be considered before 12 weeks while the possibility of an alternative underlying disease is also being assessed
	+ In addition to the clinical case definitions, the term ‘long COVID’ is commonly used to describe the signs and symptoms that continue or develop after acute COVID-19. It includes both ongoing symptomatic COVID-19 (from 4 to 12 weeks) and post-COVID-19 syndrome (12 weeks or more). [46]

A clinical rehabilitation guideline for people with long COVID in Aotearoa New Zealand was released by the Ministry of Health on 15 September 2022. [1] This establishes a clear and standardised definition and supports diagnosis of long COVID in the local context. Clinical codes are now available across primary and secondary care in Aotearoa New Zealand. By coding individuals with a condition, it is possible to determine the prevalence more accurately. This will lead to consistent data collection, analysis, and reporting which is essential for an accurate estimate of the prevalence of long COVID in the population and to allow a better understanding of the impacts of long COVID in Aotearoa New Zealand.[46]

Other widely used international definitions have been developed by the World Health Organization ([WHO](https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1%20.)) and Centers for Disease Control and Prevention ([CDC](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html)). Definitions have also been developed for sub-populations of interest including children using the Delphi method, aligning with the WHO guidelines. [47] The resulting definition was outlined as

“Post-COVID-19 condition occurs in young people with a history of confirmed SARS-CoV-2 infection, with at least one persisting physical symptom for a minimum duration of 12 weeks after initial testing that cannot be explained by an alternative diagnosis. The symptoms have an impact on everyday functioning, may continue or develop after COVID infection, and may fluctuate or relapse over time”.

#### Symptoms and Signs

There are **a range of signs and symptoms** that have been associated with long COVID. These vary greatly, with studies indicating that over 100 symptoms have been associated with long COVID. [2, 3] Symptoms can be respiratory, cardiopulmonary, neurological, or generalised, as detailed in Table 1 below. [48]

 **The most reported symptoms of long COVID are fatigue or general malaise, headaches, cognitive impairment or attention disorders, or respiratory symptoms. [2, 49]**

Table 1: Commonly reported symptoms of long COVID

|  |  |
| --- | --- |
| **Cardiopulmonary*** Difficulty breathing or shortness of breath
* Cough
* Chest pain, tightness, or heaviness[[2]](#footnote-3)
* Palpitations

**Neurological*** Cognitive impairment (‘brain fog’, loss of concentration or memory issues)
* Headache
* Sleep disturbance
* Peripheral neuropathy symptoms (pins and needles, numbness)
* Ongoing changes to smell or taste
* Dizziness
* Delirium (in older populations)

**Musculoskeletal*** Muscle aches and pains
* Muscle weakness[[3]](#footnote-4)
* Joint pain

**Psychological/ psychiatric symptoms**[[4]](#footnote-5)* Symptoms of depression
* Symptoms of anxiety
 | **Generalised symptoms*** Fatigue
* Fever
* Pain
* Reduced exercise capacity

**Gastrointestinal** * Abdominal pain
* Nausea
* Diarrhoea
* Anorexia and reduced appetite (in older populations)

**Ear, nose, and throat*** Tinnitus
* Earache
* Sore throat
* Dizziness

**Other*** Skin rashes (including vesicular, maculopapular, urticarial, or chilblain-like lesions on the extremities)
* Metallic or bitter taste
* Metabolic disruption (such as poor control of diabetes)
* Thromboembolic conditions
 |

Evidence indicates that people experiencing long COVID generally fall into one of two symptom groups: those experiencing ongoing respiratory symptoms (including coughing and shortness of breath) combined with fatigue and headaches; and those experiencing multi-systemic symptoms, affecting the heart, brain, and gut (for example, palpitations and ‘brain fog’). [50] A report from the CDC (September 2022) suggests that people who have had COVID-19 have twice the risk of respiratory conditions or developing pulmonary embolism than those who have not had COVID-19. Furthermore, respiratory conditions had the highest risk ratios reported of conditions associated with long COVID. [49, 51]

In addition to the wide range of possible symptoms, some of the key features of long COVID include:

* Concurrence of multisystem, fluctuating and often overlapping 'clusters' of symptoms
* Symptoms that vary in severity and site over time, including symptom-free periods followed by relapses
* Symptom severity may range from mild to incapacitating
* Worsening of symptoms after physical or mental activity
* Relapses may occur in an irregular pattern or in response to specific triggers (e.g., physical, or mental activity, stress, menstruation, heat, or alcohol)
* People may experience new symptoms that were not present during the acute phase of their COVID-19 infection. [35, 37, 52]

COVID-19-associated cognitive impairment often includes impaired function relating to concentration, processing information speed, attention, and memory. [53] Evidence suggests that mild cases of COVID-19 could lead to prominent neuroinflammation, causing physical damage to the white matter in the brain. This disrupts regular cellular processes, similar to damage which occurs during chemotherapy. [54] This damage appears to contribute to the lingering neurological symptom(s) (often termed ‘brain-fog’) reported by many with long COVID or undergoing chemotherapy. A positive association is the potential for cancer therapy related treatments to provide insight into appropriate treatments for long COVID-induced neurological symptoms. [54]

There is also evidence of COVID-19 infections leading to persistent cardio-renal inflammation and activation of the haemostatic pathways, which have implications for reduced pulmonary and lung function. [55, 56]

#### Omicron

Studies suggest that while the individual risk of developing long COIVD from Omicron infections is lower than for previous variants, continued high case rates indicate that long COVID cases are expected to increase, leading to a potentially widespread impact on health systems. [57, 58]

The UK’s Office for National Statistics (ONS) suggests that despite Omicron having lower case severity there is still significant long COVID burden, largely driven by the high case numbers. [59]

BA.5 continues to be the prevalent Omicron sub-lineage across New Zealand as of November 2022 however, this proportion is decreasing as the proportion of new sub-variants increases. The effect on long COVID incidence as a result from infection with these new sub-variants is currently unknown, however literature suggests that these variants are capable of increased immune evasion due to mutations in the surface spike proteins. [60] Internationally it is estimated that second and third waves of infection due to new sub-variants are likely to increase the prevalence of long COVID, particularly amongst those in high exposure environments such as healthcare. [61]

There is no published evidence, grey literature or media reports suggesting a decline in demand for health services with Omicron, with the number of people self-reporting persistent symptoms beyond four weeks in the UK has been reported to have decreased to 2.1 million from an approximate 2.3 between September and October 2022, which may have impacted demand. However, the number reporting persistent symptoms beyond 12 weeks increased from 1.6 to 1.8 million. [62]

### Epidemiology

#### Prevalence

Various studies and meta-analyses have reported widely varying estimates of long COVID prevalence, ranging from single digit estimates[[5]](#footnote-6) to at least 80% of people following SARS-COV-2 infection. [2, 4] Some have reported at least half of people experience at least one ongoing symptom during the 6-12 months after infection. [63, 64] In a meta-analysis published in April 2022, global estimated pooled prevalence of post-COVID-19 condition was 0.43 (95% CI, 0.39-0.46). [5] Hospitalised and non-hospitalised patients had estimates of 0.54 (95% CI, 0.44-0.63) and 0.34 (95% CI, 0.25-0.46) respectively. Regional prevalence estimates were highest for Asia (0.51; 95% CI, 0.37-0.65), Europe (0.44; 95% CI, 0.32-0.56), and United States of America (0.31; 95% CI, 0.21-0.43). Global prevalence for 30, 60, 90, and 120 days after infection were estimated to be 0.37 (95% CI, 0.26-0.49), 0.25 (95% CI, 0.15-0.38), 0.32 (95% CI, 0.14-0.57), and 0.49 (95% CI, 0.40-0.59), respectively[[6]](#footnote-7). Some recent studies have reported a prevalence of closer to 20%. For example, a cross-sectional survey carried out during the BA.5 surge in the US found that an estimated 21.5% (95% CI ,18.2-24.7) of respondents with a SARS-CoV-2 infection more than four weeks prior reported long COVID symptoms. [65]

A study published in August 2022 is unique in that it corrected for symptoms present before SARS-CoV-2 infection, as well as controlling for symptom dynamics in age and sex-matched controls. [66] The occurrence of 23 symptoms were assessed in COVID-19-positive participants at 90–150 days after infection and compared with occurrence before infection and with matched controls. It was concluded that in 12.7% of patients, ongoing symptoms could be attributed to COVID-19, as 381 (21.4%) of 1782 COVID-19-positive participants versus 361 (8.7%) of 4130 COVID-19-negative controls had at least one of these core symptoms substantially increased to at least moderate severity at 90–150 days after COVID-19 diagnosis or matched timepoint.

The way in which long COVID is defined and measured will affect prevalence estimates. [39, 40]. The broader the definition, the more people will fall under this category. The severity of ongoing symptoms may vary widely. For example, the ONS in the UK estimated that as of 3 November 2022, an estimated 2.1 million people living in private households in the UK (3.3% of the population) were experiencing self-reported long COVID (symptoms continuing for more than four weeks after the first confirmed or suspected coronavirus (COVID-19) infection that were not explained by something else). Long COVID symptoms adversely affected the day-to-day activities of 1.6 million people (73% of those with self-reported long COVID), with 330,000 (16%) reporting that their ability to undertake their day-to-day activities had been “limited a lot”.[59]

Despite the limitations of studies investigating long COVID prevalence (as discussed above), there is increasing evidence that a significant number of people experience long COVID, with the potential to greatly affect health system capacities worldwide. [63] In September 2022, WHO/Europe reported on modelling that showed that an estimated 17 million people in the European Region met the WHO criteria for long COVID in 2020 and 2021. [67] The modelling indicates that there was a 307% increase in new long COVID cases identified between 2020 and 2021, driven by the rapid increase in confirmed COVID-19 cases from late 2020 and throughout 2021.

More details about prevalence estimates from some key sources, systematic reviews, and meta-analyses can be found in earlier versions of this evidence brief (see particularly 17 October 2022).

#### Prevalence of long COVID in Aotearoa New Zealand

Currently, the prevalence of long COVID in Aotearoa New Zealand is unknown. However, it is likely that some groups will be disproportionately affected given the varying rates of acute COVID-19 infection. Preliminary results from the Ngā Kawekawe o Mate Korona study suggest that the prevalence may vary across groups. Of 65 Māori participants, 43% (28/65) reported symptoms for more than one month, and of these participants, 75% (21/65) reported experiencing long COVID symptoms for more than three months post-infection. In comparison, of the 405 participants who were non-Māori, 47% (190/405) reported symptoms for more than one month, and of these individuals, 65% (124/405) reported symptoms which lasted more than three months. [68] While similar proportions reported ongoing symptoms overall, slightly more Māori participants reported symptoms for three months or longer. It is not possible to draw conclusions about the overall prevalence of long COVID given that participants were self-selected into the study and there was a particular focus on recruiting Māori participants.

In Aotearoa New Zealand, Māori may have an increased risk of developing long COVID given the higher rates of COVID-19 in this group, and lower vaccination rates. The potential inequitable impact of long COVID on Māori is concerning and is receiving recent media attention. [69] While data is still emerging, it is likely that Māori will be disproportionately affected by long COVID. Māori continue to experience inequities in vaccination rates and incidence of severe illness requiring hospitalisation, both of which are associated with a higher likelihood of developing long COVID. Māori are also at greater risk of COVID-19 mortality compared with European and Other groups. [7]

With clinical codes now established for use in Aotearoa New Zealand, it will be possible to gain a clearer picture of the number of people affected. The Ministry of Health is funding several new research projects related to COVID-19, including some on long COVID in Aotearoa New Zealand, which will help give an indication of the prevalence of long COVID. One of these studies seeks to establish a registry of long COVID. [6]

#### Aetiology

Long COVID is complex and there is likely to be more than one mechanism that contributes to its development. Evidence continues to emerge on the molecular contributors to long COVID, which may inform advice for management and treatment. SARS-CoV-2 is not just a virus that affects the respiratory system; it can cause widespread tissue damage and inflammation, leading to multisystem disruption, systemic inflammation, and immune dysfunction. [8, 9] There are currently a few broad theories as to what causes long COVID symptoms. [9, 70] These factors are not mutually exclusive[[7]](#footnote-8), and include:

* persistent virus or viral antigens causing chronic inflammation [29, 71-73]
* autoimmunity triggered by SARS-CoV-2 infection [29, 74, 75]
* dysbiosis (changes in the microbiome) and viral reactivation (reactivation of viruses other than SARS-CoV-2 in the context of COVID-19 infection) [29, 76, 77]
* unrepaired tissue damage from the original infection (including endothelial dysfunction) [9, 70, 76]
* dysregulated immune reaction or immune abnormalities [29, 76, 77]
* changes to the endocrine system. [29, 78, 79]

#### Similarities between long COVID and ME/CSF

Many healthcare professionals and researchers have compared the experience of long COVID to other post-viral conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). [10-12] The most striking similarities between long COVID and ME/CSF include:

* a pattern of long-term illness being triggered in some people by acute infection of a virus [10]
* symptoms of fatigue, brain fog, headaches, pain in organs and tissues, and disturbances of the autonomic nervous system which regulates functions such as blood pressure, respiration, digestion, and sleep [11]
* they affect a similar demographic [11]
* poorly understood potential mechanisms with evidence of cellular damage, inflammation, and changes to the immune and endocrine systems. [29]

ME/CFS has a history of being poorly understood and neglected by medical establishments due to the complicated presentation of symptoms and poorly defined aetiology. [11] There remain multiple case definitions of ME/CFS and relatively little research has been carried out on the topic. Until recent years, those with ME/CFS may have had issues accessing care and support as it was considered to be a psychosomatic illness. Recent studies have now debunked this idea and molecular studies have identified it to be a complex biomedical illness that involves immune system dysfunction. [11] Immunological research is underway in New Zealand, including investigation of whether long COVID and ME/CSF share common biomarkers. [11]

#### Risk factors

There is a growing body of evidence on which groups are at greatest risk of developing persistent symptoms. Long COVID appears to be more common among people who have had severe COVID-19 symptoms during their acute illness but can also affect those who initially had mild or moderate COVID-19. Even people who initially were asymptomatic may go on to develop long COVID. [80] Some factors that may be associated with increased chance of developing long COVID symptoms include:

* older age [5, 50, 81]
* having more than one underlying chronic medical condition or pre-existing condition [82]
* pre-existing asthma [5]
* a higher body mass index (obesity) [82]
* being female[[8]](#footnote-9) [82-85]
* hospitalisation during acute COVID-19 [5, 86] - duration of long COVID symptoms may also be longer among hospitalised individuals compared to those who were not hospitalised [4]
* multiple early symptoms [87, 88]
* SARS-CoV-2 variant – there is some evidence that the risk of long COVID is less after Omicron infection compared with Delta [58]
* levels of psychological distress before SARS-CoV-2 infection [89]
* other immunological factors, [87] such as: greater viral load during early stages of infection; the presence of autoantibodies; [78] imbalances or compositional alterations in the gut microbiome, [78, 90]; vaccination status; [21] or previous Epstein-Barr virus infection or a reactivation of latent viruses during initial infection. [78, 91]

#### Risk of long COVID after reinfection

Reinfection with SARS-CoV-2 is becoming more common due to waning of immunity and increased immune evasion from emerging new variants. Although it is currently unknown to what extent reinfection puts someone at risk of worsening symptoms, it seems likely that another infection increases the risk of developing long COVID.

Anecdotal descriptions suggest that reinfection with SARS-CoV-2 can lead to worsening symptoms of long COVID. A survey published by Long COVID Support and Long COVID Kids (UK) has provided some real world evidence on the effect of reinfection. [92] It surveyed people from 30 countries and indicated that in 80% of respondents, reinfection worsened the symptoms of long COVID. However, it is important to note the potential for overestimation due to reporting bias in surveys.

Reinfection at the time of writing is often from an Omicron infection occurring after infection with a previous variant such as Delta or Alpha. Omicron reinfections after a previous Omicron infection are less common, although have been shown to occur and may become more common with emerging new variants that are more immune evasive. The translation of COVID-19 reinfections to long COVID is difficult to quantify currently and reflects the unique position of Aotearoa New Zealand which has a highly vaccinated population (>95%) and the Omicron and subsequent variants being the dominant infections in New Zealand (>93%). Emerging research overseas demonstrates the acute and lingering symptoms of an Omicron infection to be less severe than with earlier variants. [13]

It is important to note that reinfection in New Zealand is likely to become more common as time goes on, which reinforces the importance of vaccination, including boosters, for the best defence against COVID-19.

A recent study (November 2022) that used the US Veterans Affairs national healthcare data reported an increased risk of death, hospitalisation, and sequelae with reinfection compared to no reinfection. [93] These results have been widely reported; however, the results should be interpreted very carefully as the follow-up time after symptom onset is not the same in the comparison groups (no reinfection group and the reinfection group). Furthermore, it is not surprising that people who have had a reinfection recently have more symptoms than those who had one infection earlier.

### Long COVID in children

**Long COVID in children is not well described**, and the studies to date have generally been of poor quality, with some significant limitations as described above. [41-44] Persistent illness in children has been noted in some studies and in patient support groups, but its prevalence, characteristics, and duration are currently unclear. [94, 95]

Studies indicate that the length of time a child is symptomatic varies, with reports ranging from 28 days to 3 months. [42, 94] The most prevalent long COVID symptoms within children’s cohorts are fatigue or weakness, shortness of breath, cough, headaches, muscle and body aches, and fever. The most common types of activity impairments were inability to walk or exercise as much as before, sleeping more than usual, and difficulty focusing and completing schoolwork. [96-99]

Estimates of the prevalence of long COVID in children vary widely, with studies reporting rates of 4% to 66%. [42, 99-106] A systematic review and meta-analysis conducted in the US reported the estimated prevalence of long-COVID in children from 16 studies to be 25%, noting estimates range from 2% to 66%. [106] The variability in prevalence estimates have been linked to various factors including initial SARS-CoV-2 infection severity and variant type, different methodological approaches (clinical assessment vs self-report), definition of cases (diagnosed vs suspected), variable follow-up times, prevalence of pre-existing clinical conditions, size of study population and definitions used for control groups. [42, 43, 107, 108] One report suggests that over half the children and adolescents studied reported psychological and physical symptoms related to long COVID, irrespective of whether they received a positive SARS-CoV-2 diagnosis or not, though this is difficult to interpret and highlights the impact of the pandemic itself on children and adolescents. [109] There is also difficulty in interpreting results from the existing literature, as defining control groups within a population with high levels of COVID-19 infection can result in bias.

Some studies suggest that long COVID in children is less common and tends to be less protracted than in adults. [104] Other experts argue that accurately establishing how many children and adolescents experience long COVID is difficult and likely underestimated. This may be because acute SARS-CoV-2 infection is less severe in children, often making an initial definitive diagnosis less likely. [105] Long-term SARS-CoV-2 infection–associated symptoms can be difficult to distinguish from pandemic-associated symptoms. [41, 42] Studies have found that children who tested negative for COVID-19 have had similar symptoms, which are also common after other viral infections, and could also be due to the experience of lockdown and other social restrictions. [110, 111]

Given that acute COVID-19 generally poses a low risk to children, an accurate determination of the risk of long COVID is important in the debate about the risks and benefits of vaccination in this age group. [42] Similar to adults, it is likely that long COVID in children may have a greater impact on those from socioeconomically disadvantaged areas and ethnic minority groups. [44]

### Prevention through vaccination

Much of the discussion on prevention of long COVID currently focuses on the role of vaccination. Collectively, findings from various studies suggest that vaccination against COVID-19 might reduce the population prevalence of long COVID by reducing the risk of:

* continuing to experience persistent symptoms in those who already have symptoms when vaccinated
* developing persistent symptoms after breakthrough infections
* being infected in the first place
* transmitting the virus after infection. [18]

In Aotearoa New Zealand, most people are vaccinated with Pfizer and have received two or more doses. Additionally, a large proportion of people had received a complete primary vaccination course prior to community spread of COVID-19.

There continues to be no data in children about the level of protection provided by vaccination against the incidence of long COVID.

#### Vaccination prior to infection

There is a substantial amount of literature emerging that supports the hypothesis that getting vaccinated prior to infection reduces the risk of long COVID. [14-24]

Studies have suggested the following themes:

1. **The incidence of long COVID is lower in people with breakthrough infection following vaccination than in unvaccinated controls**. [18] A UK community-based matched cohort study (September 2022) reported that persistent symptoms were seen in 9.5% of breakthrough cases compared to 14.6% in the unvaccinated controls. [18]
2. **Vaccinated people are less likely to report symptoms than unvaccinated or partially vaccinated people**. [14-23] In general, vaccinated people were less likely to report the following symptoms in the medium to long term: fatigue, persistent muscle pain, headache, hair loss, weakness in arms and legs, shortness of breath, dizziness, anosmia, interstitial lung disease, myalgia, and other pain. [17] Papers reporting on this can be split into those that investigated the effect from one dose, [23] at least two doses, [21, 22], or at least 3 doses. [21-24] Only one paper identified reported that they found no difference in symptoms between vaccinated and unvaccinated people. [112]
3. **Evidence likely underestimates the effect of vaccination prior to infection on long COVID.** This is because it cannot account for all infections that were completely avoided due to vaccination.

#### Vaccination after infection

The exact effect of vaccination on pre-existing long COVID remains uncertain and contentious. Anecdotal reports and studies suggest a variety of experiences following COVID-19 vaccination ranging from improvement, deterioration, and no change in long COVID symptoms. [15, 17, 23, 25-27]

A UK Health Security Agency rapid evidence brief (January 2022) reviewed multiple studies and reported that vaccination after infection seems to be more often correlated with long COVID symptoms improving than with them worsening. However, it was most common for there to be no change in long COVID symptoms following vaccination. [15, 17] In some cases, as high as 70% of people reported no change. [15] A review (July 2022) reported that nine studies indicated vaccination likely improves the effects of long COVID, one saw a negative association between vaccination and long COVID, one saw mixed results depending on the symptoms, and one paper found no association between vaccination after infection and long COVID. [14]

Evidence relating to vaccination after infection tends to relate to the following themes:

1. **The timing of vaccination following infection:** It has been reported that people who were vaccinated sooner were less likely to report long COVID symptoms than unvaccinated people. [15, 23] People who were vaccinated within 4 weeks of infection reported four to six times less long COVID symptoms and people vaccinated between 4-8 weeks following infection reported three times less symptoms. [23] Additionally, protection is reported from vaccination as long as 12 weeks after infection. [23]
2. **Changes in long COVID symptoms after vaccination:** There are many studies that compare changes in symptoms, however these have many limitations and are hard to compare directly. A large study published in *Nature Medicine (*May 2022) used the US Veterans Affairs databases for an analysis that included more than 13 million people. [86] This reported that vaccination lowers the risk of long COVID after infection by about 15%. [26] A community-based cohort study (May 2022) of 28,356 participants from the UK’s COVID-19 Infection Survey examined the trajectory of long COVID symptoms following COVID-19 vaccination. [18, 19, 113]

In this:

* a single dose was associated with an initial 12.8% decrease in the odds of long COVID, however this was not sustained over the next 12 weeks
* a second vaccination was associated with an 8.8% decrease in the odds of long COVID, and this was sustained over the next nine weeks [18, 113]

In another study, improvement to symptoms of long COVID was reported in 23.2% of vaccinated people, compared to 15.4% in the unvaccinated cohort while a worsening of symptoms was reported in 5.6% of vaccinated people compared to 14.3% in the unvaccinated cohort. [15]

1. **Vaccine specific data:** A review of literature comparing different vaccine types has reported that most studies did not find any difference in efficacy in preventing long COVID symptoms between vaccine types. [14, 114] One study (April 2022) found a significant difference in the symptoms of long COVID reported by participants that received the Moderna vaccine compared to AstraZeneca with more reporting fatigue, myalgia, and chest pain in the Moderna cohort. [14] A report found that people who received mRNA vaccines after infection tended to report larger levels of improvement compared to adenovector vaccines. [27]

In general, it is accepted that vaccination leads to no worsening of symptoms or quality of life with some statistically significant improvements. [15] Therefore, it is widely recommended that after a COVID-19 infection, people should start or continue their vaccination schedule after three months from diagnosis with the acute illness, to allow for some time for recovery.

#### Vaccine injury

There is a theory that suggests in rare occasions vaccine injury may lead to long COVID symptoms. Some small-scale research has been undertaken however there have been no conclusive findings to suggest that the vaccine may be causing rare and lasting health problems in some people. Avidra Nath, the clinical director at the National Institute of Neurological Disorders and Stoke reported that the people had “temporal association” between their faltering health and vaccination, however it was unclear if there was “an etiological association.” In general, there was a correlation, but no defined causation between the vaccination and the long COVID symptoms. [115]

### Impacts

#### Psychosocial impacts

The functional impairment experienced by some people with long COVID and the toll managing symptoms has on quality of life is becoming clearer. Studies are reporting an overall reduction in quality of life through the onset of multiple psychosocial impacts/outcomes from long COVID including post-traumatic stress disorder (PTSD), major depressive disorder, anxiety disorders, sleep disorders, phobias, fears with avoidant behaviours, health anxieties, obsessive-compulsive disorder (OCD) and adjustment disorder related to living with long COVID-19 symptoms, social exclusion and addictions (as a form of coping), and neuropsychiatric disorders. [116-118] Researchers have also found in a systematic review that people with long COVID have increased reported rates of neuropsychiatric sequelae however, the risk of incident neuropsychiatric manifestations varied among studies. [118]

Further research into the new‑onset neuropsychiatric symptoms are required to determine evidence of a causal relationship. In the Ngā Kawekawe o Mate Korona study, 43% of Māori and 52% of non-Māori reported not feeling understood by their healthcare professional, and 61% and 76% respectively reported having concern about not knowing when their symptoms would end. [68]

#### Social and economic impacts

The financial impact of long COVID is widespread but hard to quantify given the wide variety of variables involved including decreased productivity due to a reduction in workforce, to the increased associated individual costs, including healthcare costs, lost wages, lost savings, and accrued debt. Additionally, long COVID has an impact on the ability of some patients to work. Studies have found that people with ongoing symptomatic COVID-19 or long COVID have reduced work schedules, report increased absence from work/education, reduced performance in education, and often require extra support and recovery time. [52, 119] Long COVID therefore limits the ability of people to return to work and to socialise, not only potentially further affecting their mental health, but also having economic consequences for them, their whānau, and society. [37] There is also widespread international concern regarding the long-term economic consequences of long COVID related neuropsychiatric sequelae. Young individuals who develop these neuropsychiatric conditions as the result of long COVID may have reduced ability to attend school or higher education as well as the ability to find and maintain employment. [52, 119] This could potentially lead to a widespread economic burden for future generations. [120]

Further work to fully assess the financial impact of long COVID is required as research and reporting regarding the overall financial impact and financial effects of long COVID is currently scarce. The social and economic burden of long COVID will likely affect Māori and Pacific peoples to a greater degree, as they have accounted for a greater proportion of cases during Aotearoa New Zealand’s COVID-19 outbreaks.

### Management and Support

#### Diagnosis

Currently, there are no specific tests that can be used by healthcare professionals to diagnose long COVID. Diagnosis is instead based on presentation of long COVID symptoms following a known or suspected SARS-CoV-2 infection. There are a wide range of symptoms that can present for long COVID, many of which are common to a multitude of other conditions, making them hard to decipher or confirm as long COVID. Additionally, symptoms can be diverse with multi-organ involvement, may fluctuate, vary widely, and will affect people in different ways. [28] Compounding the lack of clear diagnostic tools, due to the relative newness of the condition, there may be a limited amount of knowledge of the condition among healthcare professionals.

##### Emerging diagnostic tools

Immune profiling in conjunction with machine learning has been used to show numerous abnormalities and discrepancies between blood samples taken from long COVID patients and control cohorts. Abnormalities include: [29]

* increased cell populations that are associated with elevated inflammatory and antiviral immune responses
* marked differences between myeloid and lymphocyte populations
* evidence of elevated humoral responses against SARS-CoV-2 in long COVID patients
* differences in immune modulators and hormones.

One of the most significant differences identified to date is a pronounced decrease of cortisol which is reduced by approximately half in long COVID patients compared to healthy and convalescent controls. [29] This paper concluded, based on machine learning, that cortisol levels alone appear to be the most significant predictor of long COVID. [29] This is consistent with findings in another paper. [78]

There are a few specific platforms that use biomarkers to assist with the diagnosis of long COVID including the IncellKINE long COVID test, [121] Novel CovGENE PCR Blood Test [122], and Fourier transform-nuclear magnetic resonance (FT-NMR) spectrometer. [123]

#### Treatment

Multiple potential long COVID therapeutics are in development, however none have been clinically proven at this stage. Clinical trials investigating long COVID treatments often are currently limited by having small sample sizes, sub-optimal control groups, and target specific symptoms, such as fatigue or thrombotic events.

Some pipeline therapeutics for long COVID include:

* **Paxlovid:** an *in vitro* study has provided preliminary evidence that Paxlovid may be used as a treatment for long COVID, however there are currently no clinical trials investigating this in a patient setting. [30]
* **SNG001** (interferon-beta 1a)**:** Phase III data was presented at the Infectious Disease Week 2022 that suggested Synairgen’s inhaled antiviral treatment, SNG001, may be beneficial in reducing long COVID symptoms. This included a 35.4% reduction in fatigue/malaise, a 28.3% reduction in dyspnea, and a 61.4% improvement in people who had reported loss of taste and smell. Additionally, it was reported to reduce anxiety and depression. This data was generated in a clinical trial with endpoints focused on acute COVID-19 treatment. Further evidence is required to support the use of SNG001 in long COVID treatment. [31]
* **Antihistamines:** There is some initial evidence from a small study (n=65) that suggests that antihistamines may improve long COVID symptoms. [32]
* **Dietary supplements:** A small US clinical trial (n=51) has identified a nutraceutical formulation (including β-caryophyllene, pregnenolone and seven other compounds) for the treatment of long COVID. When looking at 12 specific symptoms in long COVID patients, the study reported a significant attenuation of symptoms in 72-84% of participants. [33]. Limitations to this study include its small numbers of participants and open-label study design.

#### Models of care

Currently the mainstay of long COVID management is supportive and holistic care, symptom control, and detection of treatable complications. [124] Evidence for interventions to improve long COVID symptoms is limited, [125] however there is a consensus that the best practice for treatment and rehabilitation of long COVID needs to be a multidisciplinary, multispecialty approach. [35, 37, 124, 126-130] This will support the wide-ranging and multi-organ nature of symptoms. Specific symptom management will usually be pragmatic, with avoidance of over-investigation. [126, 130]

It is proposed that models of care should include an assessment and case management plan that is developed and tailored to match how the disease manifests for each patient [37, 126]. Services should also allow for sufficient time for the clinic visit and have the ability for follow-up. [129] Some patients may find it useful to keep track of their symptoms to help better understand them, identify which impact them most, and identify patterns and changes. [127]

International studies have explored the use of physical activity-based rehabilitation, neurocognitive rehabilitation, as well as physical and psychological re-conditioning. [131] Key services that have been identified as tools for those struggling with fatigue include physical therapy, physiotherapy, and occupational therapy. Additionally, important specialists may include experts in the fields of internal medicine, infectious disease, pulmonology, cardiology, ophthalmology, psychology, physical medicine, ear, nose and throat, speech pathology, and neurology. [35] Nutritional support has also been important, with lethargy having flow-on effects onto the ability to cook and prepare food, resulting in some struggling with malnutrition. [128] Several of the studies delivered interventions via non-face to face digital means, including telehealth/rehabilitation, [132-135] app based [136, 137] or virtual reality devices. [138, 139]

There are several case reports endorsing supervised exercise and education programmes. The studies advocate for multidisciplinary rehabilitation to reduce disability and improve functionality [140] and quality of life [141]; improvements in six-minute walk test, dyspnoea scores [142] and anxiety scales. [143, 144]

Internationally, many countries are implementing dedicated treatment guidelines, care pathways and useful online resources to support patients with long COVID. This includes:

* opening long COVID clinics as one-stop-shops for treatment and support [35, 145]
* developing online resources such as:
	+ informative websites that provide symptom-based suggestions to manage long COVID at home [146]
	+ websites (such as Altea Long COVID Network) which provide a meeting place for those affected, relatives, medical professionals, researchers, and other interested parties. [147]
* Creating new frameworks to establish coordinated rehabilitation care pathways across the care continuum specifically targeting in-hospital care, continuing care, and community-based care. (e.g., the Provincial Post COVID-19 Rehabilitation Response Framework in Alberta, Canada). [148]

For children, New Zealand specific resources are available online, including:

* Recovering From COVID – Including long COVID [149]
* Back to Activity and Sport After COVID-19 [150]

Some studies have also explored the role complementary and alternative medicine may have in long COVID management. [125, 154-158] These include the uses of essential oils, oral supplements, aromatherapy, and Traditional Chinese Medicine. The effectiveness of most complementary and alternative medicine interventions still needs evaluation.

#### Models of care in Aotearoa New Zealand

In September 2022, Aotearoa New Zealand resources for symptom management were published by Te Whatu Ora Waitemāta [159] and Manatū Hauora. [1] Te Whatu Ora Waitemātā have developed Aotearoa New Zealand contextualised patient resources which includes guidance on what long COVID is. It shares tips and tricks for managing long COVID and looking after yourself, ensuring people with long COVID tend to not only their physical health but all aspects of Te Whare Tapa Whā, including advice for self-care, eating well, and relaxation. Specific guidance on coping with brain fog or cognitive changes is included, as well as guidance on managing fatigue and pacing, headaches, and keeping track of symptoms.

[Rongoā Māori (Māori medicine](https://www.tepapa.govt.nz/discover-collections/read-watch-play/maori/maori-medicine#:~:text=M%C4%81ori%20medicine%20Rongo%C4%81%20M%C4%81ori,passed%20down%20through%20many%20generations)) where ailments are treated in a holistic manner is also of cultural significance for Aotearoa populations. A scoping review is underway to examining the barriers and facilitators for Māori accessing injury and rehabilitation services, and the findings will be of benefit when considering long COVID rehabilitation for the priority populations affected by long COVID. [160]

##### Equity considerations in models of care

Research was undertaken with an underserved community in the UK which discussed preferences of individuals in relation to their support for self-managed recovery from long COVID. [161] Patient and peer support networks have played a key role in the initial response to long COVID predominantly on social media platforms Facebook and Twitter. Further research was undertaken in the US to study receipt of outpatient rehabilitation services within six months of COVID-19 diagnosis and incidence of long COVID symptoms. [162] The study reported being African American was associated with lower utilisation of out-patient rehabilitation services despite a similar incidence of long COVID symptoms. Further research is needed to better understand barriers to rehabilitation services and address ethnic inequalities in receipt of care. For Aotearoa New Zealand, using an equity lens with a co-design approach with affected communities of those living with long COVID, particularly Māori and Pacific peoples, will be essential.

#### Evaluation of services

A scoping review [163] aimed to identify key concepts and knowledge gaps for long COVID by conducting a review of literature on the condition's management by United Kingdom GPs. Six key themes were identified which impact on the delivery of services:

* GP uncertainty
* assessment and monitoring of symptoms
* coordinating access to appropriate services
* listening and empathy
* facilitating provision of continual and integrated multidisciplinary care
* the need to provide or facilitate psychological support.

The findings highlight that GPs have a key role in the management of long COVID, and that patient care can be improved through better understanding of patient experiences, standardised approaches for symptom identification and treatment, and facilitation of access to multidisciplinary specialist services when needed. GPs need to be well resourced and upskilled to provide clear support.

The use of virtual rehabilitation, [164] telemonitoring, [165] and mobile healthcare for rural areas [166] were all identified in the literature as service models for delivery of care in long COVID patients. High patient satisfaction was one of the outcomes from studies utilising these service models. [132-135]

Olfactory training has also been studied for the treatment of persistent olfactory disorders however the outcomes of the study were not conclusive as beneficial. [167]

#### International guidelines on rehabilitation and management

Existing international guidelines propose that the initial management of long COVID should be in primary care and should include a series of investigations both to characterise how the individual is affected and to exclude other conditions that may coexist. Management, referrals, and care pathways should then be tailored to the manifestations of disease, including investigation and referral for signs of involvement of different organ systems. [37, 148]

The patient voice has been critical in shaping awareness of long COVID internationally and within New Zealand, and patient- and whānau-centred care should continue to be the focus. Counselling and psychological support may be needed to address high rates of poor mental health, and many of the post-COVID clinics set up throughout the US and UK contain psychology services or referrals. [168] Timely access to good quality information to understand their illness, managing expectations of others, as well as positive contact with people who have previously been through this illness also assist in an individual’s recovery. [124, 169]

There are several guidelines available for clinical management of patients with long COVID, as shown in Table 2 below.

Table 2: International guidelines for clinical management of patients with long COVID

| **Source** | **Title** | **Date** |
| --- | --- | --- |
| Agency for Clinical Innovation, Australia [170] | Clinical practice guide for assessment and management of adults with post-acute sequelae of COVID-19 Guidance for NSW health clinicians | Original Publication Date 14 May 2022, Review Date 1 August 2022 |
| Centers for Disease Control and Prevention (CDC), USA [171]  | Post-COVID Conditions: Information for Healthcare Providers | 22 Sept 2022  |
| Chartered Society of Physiotherapy, UK [172] | COVID-19 Rehabilitation Standards | Original version published 14 July 2021Updated 27 August 2021 |
| National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN) and Royal College of General Practitioners (RCGP), UK [45]  | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Version 1.20 published on 3.11.2022 |
| Ontario Health, Canada [173]  | Post-COVID-19 Condition: Guidance for Primary Care | Dec 2021 |
| Royal Australian College of General Practitioners, Australia [174] | Caring for Patients with Post COVID-19 Syndrome  | May 2022  |
| Scottish Intercollegiate Guidelines Network (SIGN), Scotland [175]  | Managing the long-term effects of COVID-19 | Original version published Dec 2020 Updated November 2021 |

#### Policy responses

Globally countries are at varying stages of their response to COVID-19, with some only having experienced significant outbreaks following the emergence of the Omicron variant. This has resulted in a lack of first-hand experience in addressing long COVID and under-developed systems capable of reporting and responding to increasing burden from long COVID.

All COVID-19 related policies in Aotearoa New Zealand require partnership and shared decision-making with key affected communities, including those with long COVID, the Māori Health Authority, the Ministry for Pacific Peoples, and Whaikaha – Ministry for Disabled People.

**Australia:** An inquiry into the health, social, educational, and economic impacts of long COVID and repeated COVID infections was launched in September 2022 by the House Health Committee. [176]

**United Kingdom:** 80 clinics focusing on providing support to those suffering from long COVID have been established with a primary focus on psychological and physiological support services. The UK government has made Statutory Sick Payments, Universal Credit or Employment and Support Allowance available to people if long COVID affects the ability to work. Affected individuals also qualify for a Personal Independence Payment if they have mobility difficulties. The UK’s response has endeavoured to provide all information in accessible and age-appropriate formats so that people can understand and take part in decisions about their care, as guided by the NICE guidelines on shared decision making and good patient experiences. [177, 178]

**United States:** As of July 2021, long COVID can be considered a disability under the Americans with Disabilities Act. Federal agencies have been asked to support patients and doctors by providing science-based best practices for treating long COVID, maintaining access to insurance coverage, and protecting the rights of workers.

**France:** On 17 March 2022, the French Health Minister published a statement recognising long COVID as a health concern in France and acknowledging the necessity for ongoing research into its prevalence, diagnosis, and treatment.

**Germany:** The German Government intends to a nationwide network of 2,580 competence centres and interdisciplinary outpatient clinics to further research and ensure needs-based care around the long-term effects of COVID-19. German physicians have also established a national association containing thirteen specialised working groups, to promote research and improve long COVID treatment. The Federal Ministry of Health has recently changed the national testing guidelines, as free access to testing for asymptomatic citizens as been removed. [179]

**Sweden:** The Swedish government has supported research on COVID-19 through funding to the Swedish Research Council and tasked the Swedish Agency for Health and Care Services Analysis with mapping long COVID care across the country. The National Board of Health and Welfare has produced guidelines and statistical reports to support the health and welfare system in meeting the needs of patients with long COVID. However, the systems for testing, assessment, treatment, and support are still being developed and are not yet fully functioning.

### References

1. Ministry of Health. Clinical Rehabilitation Guideline for People with Long COVID in Aotearoa New Zealand 2022 [updated 15 September 2022. Available from: <https://www.health.govt.nz/publication/clinical-rehabilitation-guideline-people-long-covid-aotearoa-new-zealand>.

2. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis 2021 [updated 2021/08/09. 16144]. Available from: <https://doi.org/10.1038/s41598-021-95565-8>.

3. Hayes LD, Ingram J, Sculthorpe NF. More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review [Systematic Review]. 2021 [updated 2021-November-01. Available from: <https://www.frontiersin.org/article/10.3389/fmed.2021.750378>.

4. Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022.

5. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review 2022 [Available from: <https://doi.org/10.1093/infdis/jiac136>.

6. Ministry of Health. COVID-19 and National Immunisation Programme research projects 2022 [updated 19 October 2022. Available from: <https://www.health.govt.nz/our-work/research-and-innovation/covid-19-and-national-immunisation-programme-research-projects>.

7. Ministry of Health. COVID-19 Mortality in Aotearoa New Zealand: Inequities in Risk 2022 [Available from: <https://www.health.govt.nz/publication/covid-19-mortality-aotearoa-new-zealand-inequities-risk>.

8. Brooks A. Immunity and Pathology. Long COVID: Journeying together through the fog (webinar): University of Otago, Wellington; 2022.

9. Hurst M. Long COVID (webinar). Goodfellow Unit; 2022.

10. Newman M. Chronic fatigue syndrome and long covid: moving beyond the controversy 2021 [updated 24 June 2021. 24 June 2021:[n1559]. Available from: <https://www.bmj.com/content/373/bmj.n1559>.

11. Hall M. Is Long Covid a new type of chronic fatigue syndrome? RNZ2021 [Available from: <https://www.rnz.co.nz/news/what-you-need-to-know/456714/is-long-covid-a-new-type-of-chronic-fatigue-syndrome>.

12. Pustake M, Tambolkar I, Giri P, Gandhi C. SARS, MERS and CoVID-19: An overview and comparison of clinical, laboratory and radiological features 2022 [10-7]. Available from: [https://journals.lww.com/jfmpc/Fulltext/2022/01000/SARS,\_MERS\_and\_CoVID\_19\_\_An\_overview\_and.3.aspx](https://journals.lww.com/jfmpc/Fulltext/2022/01000/SARS%2C_MERS_and_CoVID_19__An_overview_and.3.aspx).

13. Krishna BA, Metaxaki M, Wills MR, Sithole N. Reduced Incidence of Long Coronavirus Disease Referrals to the Cambridge University Teaching Hospital Long Coronavirus Disease Clinic 2022 [cited ciac630. Available from: <https://doi.org/10.1093/cid/ciac630>.

14. Mumtaz A, Sheikh AAE, Khan AM, Khalid SN, Khan J, Nasrullah A, et al. COVID-19 Vaccine and Long COVID: A Scoping Review 2022 [1066]. Available from: <https://www.mdpi.com/2075-1729/12/7/1066>.

15. Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Are vaccines safe in patients with Long COVID? A prospective observational study 2021 [2021.03.11.21253225]. Available from: <http://medrxiv.org/content/early/2021/03/14/2021.03.11.21253225.1.abstract>.

16. Mahase E. Covid-19: Vaccinated people are less likely to get long covid, review finds 2022 [o407]. Available from: <http://www.bmj.com/content/376/bmj.o407.abstract>.

17. UK Health Security Agency. The effectiveness of vaccination against long COVID. A rapid evidence briefing 2022 [Available from: <https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=fe4f10cd3cd509fe045ad4f72ae0dfff>.

18. Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study 2022 [e069676]. Available from: <http://www.bmj.com/content/377/bmj-2021-069676.abstract>.

19. Sivan M, Greenhalgh T, Milne R, Delaney B. Are vaccines a potential treatment for long covid? 2022 [o988]. Available from: <http://www.bmj.com/content/377/bmj.o988.abstract>.

20. Mahase E. Covid-19: Do vaccines work against omicron-and other questions answered England2021 [n3062]. Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=pmnm&NEWS=N&AN=34893476>.

21. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study 2022 [updated 2022/01/01/. 43-55]. Available from: <https://www.sciencedirect.com/science/article/pii/S1473309921004606>.

22. ONS. Self-reported long COVID after two doses of a coronavirus (COVID-19) vaccine in the UK: 26 January 2022 2022 [Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidaftertwodosesofacoronaviruscovid19vaccineintheuk/26january2022>.

23. Simon MA, Luginbuhl RD, Parker R. Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and Up to 12 Weeks After 2021 [2021.11.17.21263608]. Available from: <http://medrxiv.org/content/early/2021/11/18/2021.11.17.21263608.abstract>.

24. Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers 2022 [Available from: <https://doi.org/10.1001/jama.2022.11691>.

25. Tsuchida T, Hirose M, Inoue Y, Kunishima H, Otsubo T, Matsuda T. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID [<https://doi.org/10.1002/jmv.27689>]. John Wiley & Sons, Ltd; 2022 [updated 2022/07/01. 3416-20]. Available from: <https://doi.org/10.1002/jmv.27689>.

26. Reardon S. Long COVID risk falls only slightly after vaccination, huge study shows: Nature News; 2022 [updated 25 May 2022. Available from: <https://www.nature.com/articles/d41586-022-01453-0>.

27. Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID 2022 [652]. Available from: <https://www.mdpi.com/2076-393X/10/5/652>.

28. Maltezou HC, Pavli A, Tsakris A. Post-COVID Syndrome: An Insight on Its Pathogenesis 2021 [updated May 12PMC8151752]. 2021/06/03:[Available from: <https://www.mdpi.com/2076-393X/9/5/497>.

29. Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. Distinguishing features of Long COVID identified through immune profiling 2022 [2022.08.09.22278592]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/08/10/2022.08.09.22278592.full.pdf>.

30. Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19 2022 [2022.11.03.22281783]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2022/11/05/2022.11.03.22281783.full.pdf>.

31. Synairgen. SPRINTER Long COVID data presented at IDWeek 2022 [updated 20 September 2022. Available from: <https://www.synairgen.com/media/sprinter-long-covid-data-presented-at-idweek>.

32. Glynne P, Tahmasebi N, Gant V, Gupta R. Long-COVID following mild SARS CoV-2 infection: characteristic T cell alterations and response to antihistamines 2021 [2021.06.06.21258272]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2021/06/07/2021.06.06.21258272.full.pdf>.

33. Gaylis NB, Kreychman I, Sagliani J, Mograbi J, Gabet Y. The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID [Original Research]. 2022 [updated 2022-October-25. Available from: <https://www.frontiersin.org/articles/10.3389/fnut.2022.1034169>.

34. Leung TYM, Chan AYL, Chan EW, Chan VKY, Chui CSL, Cowling BJ, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review: Taylor & Francis; 2020 [2190-9]. Available from:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586446/>.

35. National Institute for Health Research. Living with COVID19 2020 [updated 15 October 2020. Available from: <https://evidence.nihr.ac.uk/themedreview/living-with-covid19/#Conclusions>

36. The Royal Society. Long Covid: what is it, and what is needed? 2020 [updated 23 October 2020. Available from: <https://royalsociety.org/-/media/policy/projects/set-c/set-c-long-covid.pdf>

37. World Health Organization (WHO). Policy Brief 39: In the wake of the pandemic - Preparing for Long COVID Copenhagen, Denmark: WHO,; 2021 [Available from: <https://apps.who.int/iris/bitstream/handle/10665/339629/Policy-brief-39-1997-8073-eng.pdf>.

38. Martin C, Luteijn M, Letton W, Robertson J, McDonald S. A model framework for projecting the prevalence and impact of Long-COVID in the UK: Public Library of Science; 2021 [e0260843-e]. Available from: <https://pubmed.ncbi.nlm.nih.gov/34855874>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639065/>.

39. Woodrow M, Carey C, Ziauddeen N, Thomas R, Akrami A, Lutje V, et al. Systematic review of the prevalence of Long Covid 2022 [2022.11.06.22281979]. Available from: <http://medrxiv.org/content/early/2022/11/07/2022.11.06.22281979.abstract>.

40. Meyerowitz-Katz G. How Many People Get Long Covid? Why the answer is more complicated than you might think 2022 [updated 4 August 2022. Available from: <https://gidmk.medium.com/how-many-people-get-long-covid-15d2e433a846>.

41. Murdoch Children's Research Institute (MCRI). Research Brief: COVID-19 and Child and Adolescent Health Victoria, Australia: MCRI,; 2021 [updated 13 September 2021. Version 1:[Available from: <https://www.mcri.edu.au/sites/default/files/media/documents/covid-19-and-child-and-adolescent-health-140921.pdf>.

42. Zimmermann P, Pittet LF, Curtis N. How Common is Long COVID in Children and Adolescents? 2021 [Available from: <https://journals.lww.com/pidj/Fulltext/2021/12000/How_Common_is_Long_COVID_in_Children_and.20.aspx>.

43. Radtke T, Ulyte A, Puhan MA, Kriemler S. Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents 2021 [869-71]. Available from: <https://doi.org/10.1001/jama.2021.11880>.

44. Munblit D, Sigfrid L, Warner JO. Setting Priorities to Address Research Gaps in Long-term COVID-19 Outcomes in Children 2021 [1095-6]. Available from: <https://doi.org/10.1001/jamapediatrics.2021.2281>.

45. NICE SaR. COVID-19 rapid guideline: managing the longterm effects of COVID-19 2021 [NICE, SIGN and RCGPs Rapid Guideline Managing Long term effects of C-19]. Available from: <https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742>

46. Angamuthu N, Geraldine Gagasa E, Baker D, Tsui J, Evan D'Souza R. Transmission of infection among health care personnel performing surgical tracheostomies on COVID-19 patients 2021 [cited Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions(R) <1946 to June 14, 2021> Search Strategy: . Available from: <http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medp&NEWS=N&AN=33722466>.

47. Stephenson T, Allin B, Nugawela MD, Rojas N, Dalrymple E, Pinto Pereira S, et al. Long COVID (post-COVID-19 condition) in children: a modified Delphi process 2022 [674-80]. Available from: <https://adc.bmj.com/content/archdischild/107/7/674.full.pdf>.

48. Cau R, Faa G, Nardi V, Balestrieri A, Puig J, Suri JS, et al. Long-COVID diagnosis: From diagnostic to advanced AI-driven models 2022 [updated 2022/03/01/. 110164]. Available from: <https://www.sciencedirect.com/science/article/pii/S0720048X22000146>.

49. Bull-Otterson L BS, Saydah S, et al. . Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021 2022 [723-17].

50. COVID Symptom Study. Long COVID: What do we know so far? 2021 [updated 12 April 2021. Available from: <https://covid.joinzoe.com/post/long-covid-what-we-know>.

51. Centers for Disease Control and Prevention (CDC). People More Likely to Develop Long COVID 2022 [Available from: <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html#:~:text=Estimates%20of%20the%20proportion%20of,among%20patients%20who%20were%20hospitalized>.

52. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188] 2021 [updated 11 November 2021. Available from: <https://www.nice.org.uk/guidance/ng188>.

53. Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review 2021 [e2111417-e]. Available from: <https://doi.org/10.1001/jamanetworkopen.2021.11417>.

54. Fernández-Castañeda A, Lu, P., et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation 2022 [updated 12 June 2022. Available from: <https://doi.org/10.1016/j.cell.2022.06.008>.

55. Multisystem involvement is common in post-COVID-19 syndrome 2022 [updated 2022/06/01. 1139-40]. Available from: <https://doi.org/10.1038/s41591-022-01838-8>.

56. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review 2021 [e005427]. Available from: <http://gh.bmj.com/content/6/9/e005427.abstract>.

57. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 2022 [updated 2022/06/18/. 2263-4]. Available from: <https://www.sciencedirect.com/science/article/pii/S0140673622009412>.

58. Antonelli MP, J.C., et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 2022 [updated 18 June 2022. 2263-4]. Available from: <https://www.sciencedirect.com/science/article/pii/S0140673622009412>.

59. Office for National Statistics UK. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 3 November 2022 2022 [Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/latest>.

60. Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin K-M, Muñoz Sandoval D, et al. Immune boosting by B. 1.1. 529 (Omicron) depends on previous SARS-CoV-2 exposure 2022 [eabq1841]. Available from: <https://www.science.org/doi/abs/10.1126/science.abq1841>.

61. Pagel C. The covid waves continue to come: British Medical Journal Publishing Group; 2022 [Available from: <https://www.bmj.com/content/377/bmj.o1504>.

62. UK OfNS. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 3 November 2022 Office for National Statistics UK2022 [Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/3november2022>.

63. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review 2021 [e2128568-e]. Available from: <https://doi.org/10.1001/jamanetworkopen.2021.28568>.

64. Zeng N, Zhao Y-M, Yan W, Li C, Lu Q-D, Liu L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action 2022 [updated 2022/06/06. Available from: <https://doi.org/10.1038/s41380-022-01614-7>.

65. Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Jones H, McNairy M, et al. The prevalence of SARS-CoV-2 infection and long COVID in US adults during the BA.5 surge, June-July 2022. medRxiv. 2022:2022.09.04.22279588.

66. Ballering AV, van Zon SKR, olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. The Lancet. 2022;400(10350):452-61.

67. World Health Organization. At least 17 million people in the WHO European Region experienced long COVID in the first two years of the pandemic; millions may have to live with it for years to come 2022 [updated 13 September 2022. Available from: <https://www.who.int/europe/news/item/13-09-2022-at-least-17-million-people-in-the-who-european-region-experienced-long-covid-in-the-first-two-years-of-the-pandemic--millions-may-have-to-live-with-it-for-years-to-come>.

68. Victoria University of Wellington. Impacts of Long COVID in Aotearoa New Zealand 2022 [Available from: <https://az659834.vo.msecnd.net/eventsairaueprod/production-otago-public/807dc49eb03f42ee8ae809865bd972eb>.

69. Tahana J. Fears equity disaster on the horizon as threat of long Covid among Māori emerges: Radio New Zealand; 2022 [Available from: <https://www.rnz.co.nz/news/te-manu-korihi/469058/fears-equity-disaster-on-the-horizon-as-threat-of-long-covid-among-maori-emerges>.

70. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review: Taylor & Francis; 2022 [updated 2022/12/31. 1473-87]. Available from: <https://doi.org/10.1080/07853890.2022.2076901>.

71. Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rössler A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases: Elsevier; [495-506.e8]. Available from: <https://doi.org/10.1053/j.gastro.2022.04.037>.

72. Denise Goh JCTL, Sonia Bilbao Fernández et al. . Persistence of residual SARS-CoV-2 viral antigen and RNA in tissues of patients with long COVID-19, PREPRINT 2022 [updated 21 Feburary 2021. Available from: <https://www.researchsquare.com/article/rs-1379777/v1>.

73. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae 2022 [cited ciac722. Available from: <https://doi.org/10.1093/cid/ciac722>.

74. Mobasheri L, Nasirpour MH, Masoumi E, Azarnaminy AF, Jafari M, Esmaeili SA. SARS-CoV-2 triggering autoimmune diseases 2022 [updated JunPMC8979824]. 20220405:[155873]. Available from: <https://pubmed.ncbi.nlm.nih.gov/35461172/>.

75. Giannos P, Prokopidis K. Gut dysbiosis and long COVID-19: Feeling gutted. 2022 [PMC9088471.]. 2917-8]. Available from: <https://pubmed.ncbi.nlm.nih.gov/35233795/>.

76. Frere JJ, Serafini RA, Pryce KD, Zazhytska M, Oishi K, Golynker I, et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations post recovery [eabq3059]. Available from: <https://www.science.org/doi/abs/10.1126/scitranslmed.abq3059>

77. Kundura L, Cezar R, André S, Campos-Mora M, Lozano C, Vincent T, et al. Low perforin expression in CD8+ T lymphocytes during the acute phase of severe SARS-CoV-2 infection predicts long COVID [Original Research]. 2022 [updated 2022-October-20. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2022.1029006>.

78. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae 2022 [updated 2022/03/03/. 881-95.e20]. Available from: <https://www.sciencedirect.com/science/article/pii/S0092867422000721>.

79. Topol E. Some Light on Long Covid: A cluster of new data Ground Truths2022 [Available from: <https://erictopol.substack.com/p/some-light-on-long-covid>.

80. Centers for Disease Control and Prevention (CDC). Post-COVID Conditions: Overview 2021 [updated 9 July 2021. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Fclinical-care%2Flate-sequelae.html>.

81. Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records 2022 [updated 2022/06/28. 3528]. Available from: <https://doi.org/10.1038/s41467-022-30836-0>.

82. Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK 2021 [2021.06.24.21259277]. Available from: <http://medrxiv.org/content/early/2021/07/10/2021.06.24.21259277.abstract>.

83. Stewart S, Newson L, Briggs TA, Grammatopoulos D, Young L, Gill P. Long COVID risk - a signal to address sex hormones and women's health: Elsevier; 2021 [Available from: <https://doi.org/10.1016/j.lanepe.2021.100242>.

84. Sylvester SV, Rusu R, Chan B, Bellows M, O’Keefe C, Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review: Taylor & Francis; 2022 [1-9]. Available from: <https://doi.org/10.1080/03007995.2022.2081454>.

85. IHME. WHO: At least 17 million people in the WHO European Region experienced long COVID in the first two years of the pandemic; millions may have to live with it for years to come 2022 [updated 13 September 2022. Available from: <https://www.healthdata.org/news-release/who-least-17-million-people-who-european-region-experienced-long-covid-first-two-years>.

86. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection 2022 [updated 2022/07/01. 1461-7]. Available from: <https://doi.org/10.1038/s41591-022-01840-0>.

87. Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome 2022 [updated 2022/01/25. 446]. Available from: <https://doi.org/10.1038/s41467-021-27797-1>.

88. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID 2021 [updated 2021/04/01. 626-31]. Available from: <https://doi.org/10.1038/s41591-021-01292-y>.

89. Wang S, Quan L, Chavarro JE, Slopen N, Kubzansky LD, Koenen KC, et al. Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection With Risk of Post–COVID-19 Conditions. JAMA Psychiatry. 2022.

90. Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC-Y, Ng SSS, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome 2022 [544]. Available from: <http://gut.bmj.com/content/71/3/544.abstract>.

91. Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation: MDPI; 2021 [763]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233978/>.

92. Long COVID Kids. A World First: Effect of Covid Reinfection on People Living With Long Covid 2022 [updated 8 September 2022. Available from: <https://www.longcovidkids.org/post/a-world-first-effect-of-covid-reinfection-on-people-living-with-long-covid>.

93. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection 2022 [updated 2022/11/10. Available from: <https://doi.org/10.1038/s41591-022-02051-3>.

94. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2: Elsevier; 2021 [708-18]. Available from: [https://doi.org/10.1016/S2352-4642(21)00198-X](https://doi.org/10.1016/S2352-4642%2821%2900198-X).

95. Sigfrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol 2021 [2021.03.18.21253888]. Available from: <http://medrxiv.org/content/early/2021/03/23/2021.03.18.21253888.abstract>.

96. Maddux AB, Berbert L, Young CC, Feldstein LR, Zambrano LD, Kucukak S, et al. Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C 2022 [cited e2022057798. Available from: <https://doi.org/10.1542/peds.2022-057798>.

97. Stephenson T, Pinto Pereira SM, Shafran R, de Stavola BL, Rojas N, McOwat K, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study: Elsevier; 2022 [Available from: [https://doi.org/10.1016/S2352-4642(22)00022-0](https://doi.org/10.1016/S2352-4642%2822%2900022-0).

98. Morrow AKMN, Rowena PhD; Vargas, Gray PhD; Jashar, Dasal Tenzin PhD; Henning, Ellen PhD; Stinson, Nika PT, DPT; Malone, Laura A. MD, PhD. . Postacute/Long COVID in Pediatrics: Development of a Multidisciplinary Rehabilitation Clinic and Preliminary Case Series. 2022 [1140-7]. Available from: <https://pubmed.ncbi.nlm.nih.gov/34793374/>.

99. Funk AL, Kuppermann N, Florin TA, Tancredi DJ, Xie J, Kim K, et al. Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection 2022 [e2223253-e]. Available from: <https://doi.org/10.1001/jamanetworkopen.2022.23253>.

100. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, et al. Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19 2021 [2021.10.21.21265133]. Available from: <http://medrxiv.org/content/early/2021/10/22/2021.10.21.21265133.abstract>.

101. Office for National Statistics UK. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK 2021 [Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/alldatarelatingtoprevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk>.

102. Lewis D. Long COVID and kids: scientists race to find answers: Nature; 2021 [updated 18 November 2021. Available from: <https://www.nature.com/articles/d41586-021-01935-7?utm_source=twt_nat&utm_medium=social&utm_campaign=nature>.

103. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, et al. Preliminary evidence on long COVID in children [<https://doi.org/10.1111/apa.15870>]. John Wiley & Sons, Ltd; 2021 [updated 2021/04/09. Available from: <https://doi.org/10.1111/apa.15870>.

104. Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease: Elsevier; 2021 [e22-e3]. Available from: [https://doi.org/10.1016/S2352-4642(21)00124-3](https://doi.org/10.1016/S2352-4642%2821%2900124-3).

105. KiKKenborg Berg S, Palm, P. et al. Long COVID symptoms in SARS-CoV-2-positive children aged 0–14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study 2022 [updated 22 June 2022. Available from: [https://doi.org/10.1016/S2352-4642(22)00004-9](https://doi.org/10.1016/S2352-4642%2822%2900004-9).

106. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses 2022 [updated Jun 23; cited The authors are solely responsible for all content, and funders played no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. S.L.L. is an employee of Novartis Pharmaceutical Company; the statements presented in the paper do not necessarily represent the position of the company. The remaining authors declare no competing interests. PMC9226045]. 20220623:[9950]. Available from: <https://pubmed.ncbi.nlm.nih.gov/35739136/>.

107. Pierce CA, Herold KC, Herold BC, Chou J, Randolph A, Kane B, et al. COVID-19 and children 2022 [1144-9]. Available from: <https://www.science.org/doi/abs/10.1126/science.ade1675>.

108. Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review 2022 [updated 2022/09/15. Available from: <https://doi.org/10.1007/s00431-022-04600-x>.

109. Zimmermann P, Pittet LF, Curtis N. The Challenge of Studying Long COVID: An Updated Review: Lippincott Williams & Wilkins; 2022 [424-6]. Available from: <https://pubmed.ncbi.nlm.nih.gov/35213866>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997013/>.

110. Jason LA, Katz BZ, Shiraishi Y, Mears CJ, Im Y, Taylor R. Predictors of Post-Infectious Chronic Fatigue Syndrome in Adolescents: Routledge; 2014 [41-51]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956649/>.

111. Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome after infectious mononucleosis in adolescents 2009 [updated JulPMC2756827]. 2009/07/01:[189-93]. Available from: <https://pubmed.ncbi.nlm.nih.gov/19564299/>.

112. Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections 2021 [2021.10.26.21265508]. Available from: <https://www.medrxiv.org/content/medrxiv/early/2021/10/26/2021.10.26.21265508.full.pdf>.

113. . !!! INVALID CITATION !!! (18).

114. Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID 2022 [updated Apr 21; cited The authors declare no conflict of interest. PMC9146071]. 20220421:[Available from: <https://www.mdpi.com/2076-393X/10/5/652>.

115. Couzin-Frankel JV, G. In rare cases, coronavirus vaccines may cause Long Covid–like symptoms Science2022 [Available from: <https://www.science.org/content/article/rare-cases-coronavirus-vaccines-may-cause-long-covid-symptoms>.

116. Faghy MA, Maden-Wilkinson T, Arena R, Copeland RJ, Owen R, Hodgkins H, et al. COVID-19 patients require multi-disciplinary rehabilitation approaches to address persisting symptom profiles and restore pre-COVID quality of life: Taylor & Francis; 2022 [1-6]. Available from: <https://doi.org/10.1080/17476348.2022.2063843>.

117. Hussain FA. Facilitating care: a biopsychosocial perspective on long COVID 2022 [30-1]. Available from: <https://bjgp.org/content/bjgp/72/714/30.full.pdf>.

118. Efstathiou V, Stefanou M-I, Demetriou M, Siafakas N, Katsantoni E, Makris M, et al. New‑onset neuropsychiatric sequelae and ‘long‑COVID’ syndrome (Review) 2022 [updated 2022/11/01. 705]. Available from: <https://doi.org/10.3892/etm.2022.11641>.

119. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact 2021 [2020.12.24.20248802]. Available from: <http://medrxiv.org/content/early/2021/04/05/2020.12.24.20248802.abstract>.

120. Munblit D, Simpson F, Mabbitt J, Dunn-Galvin A, Semple C, Warner JO. Legacy of COVID-19 infection in children: long-COVID will have a lifelong health/economic impact 2022 [e2-e]. Available from: <https://adc.bmj.com/content/archdischild/107/3/e2.full.pdf>.

121. BioSpace. The First Diagnostic Test for Long COVID Will Formally Launch in Europe in September 2022 2022 [Available from: <https://www.biospace.com/article/releases/the-first-diagnostic-test-for-long-covid-will-formally-launch-in-europe-in-september-2022/>.

122. Daamen AR, Bachali P, Bonham CA, Somerville L, Sturek JM, Grammer AC, et al. COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity [Original Research]. 2022 [updated 2022-September-15. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2022.989556>.

123. Australia identifies unique biomarkers of SARS-CoV-2 acute infections, Long COVID BioSpectrum Asia Edition2022 [updated 21 September 2022. Available from: <https://biospectrumasia.com/news/91/21077/australia-identifies-unique-biomarkers-of-sars-cov-2-acute-infections-long-covid.html>.

124. Greenhalgh T, Sivan M, Delaney B, Evans R, Milne R. Long covid—an update for primary care. BMJ. 2022;378:e072117.

125. Veronese N, Bonica R, Cotugno S, Tulone O, Camporeale M, Smith L, et al. Interventions for Improving Long COVID-19 Symptomatology: A Systematic Review. Viruses [Internet]. 2022; 14(9).

126. RACGP. Caring for adult patients with post‑COVID-19 conditions East Melbourne, VIC2020 [

127. The National Institute for Health Innovation. Long COVID 2021 [Available from: <https://www.nihi.auckland.ac.nz/long-covid>.

128. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome 2021 [updated 2021/04/01. 601-15]. Available from: <https://doi.org/10.1038/s41591-021-01283-z>.

129. Dundumalla S, Barshikar, S, Niehaus, WN, Ambrose, AF, Kim, SY, Abramoff, BA. . A survey of dedicated PASC clinics: Characteristics, barriers and spirit of collaboration. 2022 [348- 56]. Available from: <https://pubmed.ncbi.nlm.nih.gov/35038230/>.

130. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care 2020 [m3026]. Available from: <https://www.bmj.com/content/bmj/370/bmj.m3026.full.pdf>.

131. Compagno S, Palermi S, Pescatore V, Brugin E, Sarto M, Marin R, et al. Physical and psychological reconditioning in long COVID syndrome: Results of an out-of-hospital exercise and psychological-based rehabilitation program 2022 [101080]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286763/>.

132. Calvo-Paniagua J, Díaz-Arribas MJ, Valera-Calero JA, Gallardo-Vidal MI, Fernández-de-Las-Peñas C, López-de-Uralde-Villanueva I, et al. A tele-health primary care rehabilitation program improves self-perceived exertion in COVID-19 survivors experiencing Post-COVID fatigue and dyspnea: A quasi-experimental study 2022 [cited The authors have declared that no competing interests exist. PMC9352012]. 20220804:[e0271802]. Available from: <https://pubmed.ncbi.nlm.nih.gov/35926004/>.

133. Bailly M, Pélissier L, Coudeyre E, Evrard B, Bingula R, Rochette C, et al. Systematic Review of COVID-19-Related Physical Activity-Based Rehabilitations: Benefits to Be Confirmed by More Robust Methodological Approaches 2022 [updated Jul 25; cited The authors declare no conflict of interest. PMC9331032]. 20220725:[Available from: <https://pubmed.ncbi.nlm.nih.gov/35897400/>.

134. Bordas-Martinez J, Matéu Gómez L, Cámara Menoyo D, López-Sánchez M, Santos S, Molina-Molina M, et al. Patient-reported outcomes measures (PROMs) and patient-reported experience measures (PREMs) of COVID-19 telerehabilitation: Prospective pilot program. Medicine (Baltimore). 2022;101(31):e29639.

135. Bordas-Martinez J, Matéu Gómez L, Cámara Menoyo D, López-Sánchez M, Santos S, Molina-Molina M, et al. Patient-reported outcomes measures (PROMs) and patient-reported experience measures (PREMs) of COVID-19 telerehabilitation: Prospective pilot program 2022 [updated Aug 5; cited C PMC9351514]. e29639]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351514/>.

136. Capin JJ, Jolley SE, Morrow M, Connors M, Hare K, MaWhinney S, et al. Safety, feasibility and initial efficacy of an app-facilitated telerehabilitation (AFTER) programme for COVID-19 survivors: a pilot randomised study. BMJ Open. 2022;12(7):e061285.

137. Lloyd-Evans PHI, Baldwin MM, Daynes E, Hong A, Mills G, Goddard ACN, et al. Early experiences of the Your COVID Recovery® digital programme for individuals with long COVID. BMJ open respiratory research. 2022;9(1):e001237.

138. Flannery T, Brady-Sawant H, Tarrant R, Davison J, Shardha J, Halpin S, et al. A Mixed-Methods Evaluation of a Virtual Rehabilitation Program for Self-Management in Post-COVID-19 Syndrome (Long COVID). International Journal of Environmental Research and Public Health [Internet]. 2022; 19(19).

139. Groenveld T, Achttien R, Smits M, de Vries M, van Heerde R, Staal B, et al. Feasibility of Virtual Reality Exercises at Home for Post-COVID-19 Condition: Cohort Study. JMIR Rehabil Assist Technol. 2022;9(3):e36836.

140. Güler T, Yurdakul FG, Acar Sivas F, Kiliç Z, Adigüzel E, Yaşar E, et al. Rehabilitative management of post-acute COVID-19: clinical pictures and outcomes 2021 [updated Dec. 20210927:[2167-75]. Available from: <https://pubmed.ncbi.nlm.nih.gov/34580754/>.

141. Nopp S, Moik F, Klok FA, Gattinger D, Petrovic M, Vonbank K, et al. Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life 2022 [593-601]. Available from: <https://www.karger.com/DOI/10.1159/000522118>.

142. Soril LJJ, Damant RW, Lam GY, Smith MP, Weatherald J, Bourbeau J, et al. The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature 2022 [updated 2022/04/01/. 106782]. Available from: <https://www.sciencedirect.com/science/article/pii/S0954611122000476>.

143. N Elliott AB, N Heron, C Ranson, J Hull , R Martin, J Elliott. Graduated Return to Play after SARS-CoV-2 infection – what have we learned and why we’ve updated the guidance British Journal of sports medicineApril 23, 2022 [Available from: <https://blogs.bmj.com/bjsm/2022/04/23/graduated-return-to-play-after-sars-cov-2-infection-what-have-we-learned-and-why-weve-updated-the-guidance/>

144. Albu S, Rivas Zozaya N, Murillo N, García-Molina A, Figueroa Chacón CA, Kumru H. Multidisciplinary outpatient rehabilitation of physical and neurological sequelae and persistent symptoms of covid-19: A prospective, observational cohort study 2021 [1-8]. Available from: <https://pubmed.ncbi.nlm.nih.gov/34559592/>.

145. Ladyzhets. Where are the long COVID clinics? 2022 [updated 3 November 2022. Available from: <https://www.sciencenews.org/article/long-covid-clinics-map-locations-prevalence>.

146. NHS England. Supporting your recovery after COVID 2022 [Available from: <https://www.yourcovidrecovery.nhs.uk/>.

147. Altea Long COVID Network Association. Long COVID: Altea informs and helps 2022 [Available from: <https://www.altea-network.com/en>.

148. Manhas KP, O’Connell P, Krysa J, Henderson I, Ho C, Papathanassoglou E. Development of a Novel Care Rehabilitation Pathway for Post-COVID Conditions (Long COVID) in a Provincial Health System in Alberta, Canada 2022 [Available from: <https://pubmed.ncbi.nlm.nih.gov/35778936/>.

149. KidsHealth. Recovering From COVID - Including Long COVID 2022 [updated 06 April 2022. Available from: <https://www.kidshealth.org.nz/recovering-covid-including-long-covid#:~:text=Most%20children%20who%20get%20COVID,taking%20longer%20to%20get%20better>.

150. KidsHealth. Back To Activity & Sport After COVID-19 2022 [updated 14 June 2022. Available from: <https://www.kidshealth.org.nz/back-activity-sport-after-covid-19>.

151. Long COVID Kids. Long COVID Kids Support Guide 2022 [Available from: <https://drive.google.com/file/d/1UN0LRhzYAAOOyfy5T-VSRIyiPyfE_rDh/view>.

152. Long COVID Kids. Cautious Tortoise [Available from: <https://drive.google.com/file/d/1cGakRek2Gua2C5IF6f_UkWSmuKmZsioP/view>.

153. Long COVID Kids. Pacing Penguins [Available from: <https://drive.google.com/file/d/1DqhwOVIjaLOqJzwHA9DhVwcSiW0Z9UxO/view>.

154. Hawkins J, Hires C, Keenan L, Dunne E. Aromatherapy blend of thyme, orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: A randomized, double-blinded, placebo controlled clinical trial. Complementary Therapies in Medicine. 2022;67:102823.

155. Jeon S-R, Kang JW, Ang L, Lee HW, Lee MS, Kim T-H. Complementary and alternative medicine (CAM) interventions for COVID-19: An overview of systematic reviews. Integrative Medicine Research. 2022;11(3):100842.

156. Yadav B, Rai A, Mundada PS, Singhal R, Rao BCS, Rana R, et al. Safety and efficacy of Ayurvedic interventions and Yoga on long term effects of COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021;22(1):378.

157. Curi ACC, Ferreira APA, Nogueira LAC, Meziat Filho NAM, Ferreira AS. Osteopathy and physiotherapy compared to physiotherapy alone on fatigue in long COVID: Study protocol for a pragmatic randomized controlled superiority trial. International Journal of Osteopathic Medicine. 2022.

158. Del Corral T, Garrido RF, Plaza-Manzano G, Fernández-de-Las-Peñas C, Navarro-Santana M, López-de-Uralde-Villanueva I. Home-based respiratory muscle training on quality of life and exercise tolerance in long-term post-COVID-19: Randomized controlled trial. Ann Phys Rehabil Med. 2022:101709.

159. Te Whatu Ora - Waitematā. Long COVID 2022 [Available from: <https://www.waitematadhb.govt.nz/hospitals-clinics/north-shore-hospital/long-covid/>.

160. Nelson V LM, Richard L, et al. Examining the barriers and facilitators for Māori accessing injury and rehabilitation services: a scoping review protocol. BMJ open. 2022;12(2):e048252.

161. Fowler-Davis S, Young R, Maden-Wilkinson T, Hameed W, Dracas E, Hurrell E, et al. Assessing the Acceptability of a Co-Produced Long COVID Intervention in an Underserved Community in the UK. International Journal of Environmental Research and Public Health. 2021;18(24):13191.

162. Hentschel CB, Abramoff BA, Dillingham TR, Pezzin LE. Race, ethnicity, and utilization of outpatient rehabilitation for treatment of post COVID-19 condition. Pm r. 2022.

163. Brennan A, Broughan J, McCombe G, Brennan J, Collins C, Fawsitt R, et al. Enhancing the management of long COVID in general practice: a scoping review 2022 [BJGPO.2021.0178]. Available from: <https://bjgpopen.org/content/bjgpoa/early/2022/06/30/BJGPO.2021.0178.full.pdf>.

164. Harenwall S, Heywood-Everett S, Henderson R, Godsell S, Jordan S, Moore A, et al. Post-Covid-19 Syndrome: Improvements in Health-Related Quality of Life Following Psychology-Led Interdisciplinary Virtual Rehabilitation 2021 [21501319211067674]. Available from: <https://journals.sagepub.com/doi/abs/10.1177/21501319211067674>.

165. Romaszko-Wojtowicz A, Maksymowicz S, Jarynowski A, Jaśkiewicz Ł, Czekaj Ł, Doboszyńska A. Telemonitoring in Long-COVID Patients—Preliminary Findings 2022 [5268]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103243/>.

166. Stallmach A, Katzer K, Besteher B, Finke K, Giszas B, Gremme Y, et al. Mobile primary healthcare for post-COVID patients in rural areas: a proof-of-concept study 2022 [updated 2022/07/13. Available from: <https://doi.org/10.1007/s15010-022-01881-0>.

167. Vandersteen C, Payne M, Dumas L, Cancian É, Plonka A, D'Andréa G, et al. Olfactory Training in Post-COVID-19 Persistent Olfactory Disorders: Value Normalization for Threshold but Not Identification 2022 [updated Jun 8; cited The authors declare no conflict of interest. PMC9224948]. 20220608:[Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224948/>.

168. Walter K. An Inside Look at a Post–COVID-19 Clinic. JAMA. 2021.

169. Skirrow P, Morris, L. Thoughts that Count [Presentation]. 2022 [Available from: <https://az659834.vo.msecnd.net/eventsairaueprod/production-otago-public/bfb8d575b3b342c7b72be4c5fb221c0c>.

170. Innovation AfC. Clinical practice guide for assessment and management of adults with post-acute sequelae of COVID-19: New South Wales Government 2022 [Available from: <https://aci.health.nsw.gov.au/__data/assets/pdf_file/0011/726878/ACI-CPG-for-assessment-and-management-of-adults-with-post-acute-sequelae-of-COVID-19.pdf>.

171. Centres for Disease Control and Prevention. Post-COVID Conditions: Overview for Healthcare Providers: Centres for Disease Control and Prevention; 2022 [Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html>.

172. UK CSoP. Covid-19 community rehabilitation: physiotherapy service delivery: Chartered Society of Physiotherapy UK; 2021 [Available from: <https://www.csp.org.uk/publications/covid-19-community-rehabilitation-physiotherapy-service-delivery>.

173. Health O. Post COVID-19 Condition: Guidance for Primary Care: Ontario Health; 2021 [Available from: <https://www.ontariohealth.ca/sites/ontariohealth/files/2021-12/PostCovidConditionsClinicalGuidance_EN.pdf>.

174. The Royal Australian College of General Practitioners (RACGP) HC. Caring for Patients with post-COVID-19 conditions The Royal Australian College of General Practitioners (RACGP)2022 [Available from: <https://www.racgp.org.au/clinical-resources/covid-19-resources/clinical-care/caring-for-patients-with-post-covid-19-conditions/introduction>.

175. Scottish Intercollegiate Guidelines Network. SIGN 161: Managing the long-term effects of COVID-19: National guidance for identification, assessment and management Edinburgh: SIGN; 2020 [updated 18 December 2020. Available from: <https://www.sign.ac.uk/media/1833/sign161-long-term-effects-of-covid19-11.pdf>.

176. Australia Po. Inquiry into Long COVID and Repeated COVID Infections Parliment of Australia 2022 [Available from: <https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/LongandrepeatedCOVID>.

177. Excellence NIfHaC. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services National Institute for Health and Care Excellence2021 [Available from: <https://www.nice.org.uk/guidance/cg138>.

178. Excellence NIFhaC. Shared decision making National Institute For Health and Care Excellence2021 [Available from: <https://www.nice.org.uk/guidance/ng197>.

179. (BMG) FMoH. Questions and answers about COVID-19 testing Federal Ministry of Health (BMG) 2022 [Available from: <https://www.bundesgesundheitsministerium.de/coronavirus/nationale-teststrategie/faq-covid-19-tests.html>.

1. Māori also have a greater risk of COVID-19 mortality compared with European and Other groups. 7. Ministry of Health. COVID-19 Mortality in Aotearoa New Zealand: Inequities in Risk 2022 [Available from: https://www.health.govt.nz/publication/covid-19-mortality-aotearoa-new-zealand-inequities-risk. [↑](#footnote-ref-2)
2. Clinical assessment is required to investigate the specific cause [↑](#footnote-ref-3)
3. Muscle weakness can be a reported symptom, and may also be clinically measured [↑](#footnote-ref-4)
4. The WHO has noted that the association between long COVID and psychiatric disorders is likely bidirectional [↑](#footnote-ref-5)
5. This meta-analysis incorporated 54 studies and 2 medical record databases with data for 1.2 million individuals (from 22 countries) who had symptomatic SARS-CoV-2 infection. In the modelled estimates, 6.2% (95% uncertainty interval [UI], 2.4%-13.3%) of individuals who had symptomatic SARS-CoV-2 infection experienced at least one of the three long COVID symptom clusters in 2020 and 2021 (after adjusting for health status before COVID-19). [↑](#footnote-ref-6)
6. The higher prevalence at 120 days was noted to possibly be due to the predominance of studies with patients who had been hospitalised. [↑](#footnote-ref-7)
7. For example, patients may have some degree of any or all of these contributing factors. It is possible there may be some sub-groups of patients in which one factor is more important than others. It is also possible that the relative importance of these factors could vary depending on the strain of the virus. [↑](#footnote-ref-8)
8. An elevated immune response is one proposed explanation for why long COVID appears to be more common in female patients. [↑](#footnote-ref-9)